Draft genome sequence of Xanthomonas sacchari strain LMG 476

We report the high-quality draft genome sequence of Xanthomonas sacchari strain LMG 476, isolated from sugarcane. The genome comparison of this strain with a previously sequenced X. sacchari strain isolated from a distinct environmental source should provide further insights into the adaptation of this species to different habitats and its evolution. (Résumé d'auteur

How to reveal subsurface defects in Kevlar® composite materials after an impact loading using infrared vision and optical NDT techniques?

An integrated system between infrared vision and optical non-destructive testing techniques can be considered a viable, robust and reliable approach for both aerospace manufacturing and in-service inspections. In this paper, infrared vision is applied in different spectral bands on two impacted panels made of aramid–phenolic composite by applying two different methods, respectively: (1) near and short-wave infrared reflectography and transmittography, and (2) mid-wave active infrared thermography. Furthermore, optical methods, namely digital speckle photography and holographic interferometry, are used as well to highlight the damages due to the impacts on the samples. Some techniques provide more straightforward detection capabilities than others for different defect types

Procurement of Covid-19 vaccines: why were legal liabilities transferred to the public sector?

he recent release of the Covid-19 vaccine supply contract between the European Commission and Astra Zeneca has caused a political and media storm about vaccine production logistics and supply issues. A lesser noticed but controversial issue revealed by the contract is that of where ultimate liabilities should lie, which has potentially far-reaching consequences for the public purse. Many commercial contracts include so-called indemnity clauses hereby one party contractually agrees to cover liabilities incurred by the other. The European Commission accepted in Article 14 of the agreement an extremely broad indemnity of the manufacturer covering almost any and every defect imaginable whether that be the vaccine’s inherent characteristics, manufacturing / distribution, and storage issues, labelling errors or even problems due to administration of the vaccine. This is a potentially significant burden to place on the state, and ultimately taxpayers